or Try an Advanced Search...

    ETF Components for BBC - Virtus LifeSci Biotech Clinical Trials ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LBPH A 0.05 2.59
    SRRK B 12.19 2.43
    SMMT D 3.15 1.96
    WVE C -0.56 1.83
    EWTX C 0.69 1.52
    APLT B 3.83 1.43
    BLTE C -2.69 1.43
    CNTA B -6.32 1.40
    ACLX C 3.69 1.36
    VRDN D 2.96 1.33
    IRON B 2.29 1.32
    RVMD C -0.05 1.20
    NRIX D -1.43 1.19
    SAVA D -17.71 1.17
    VERA B 2.72 1.07
    ERAS C 3.85 1.06
    PTGX C 11.55 1.04
    KYMR D 3.38 1.04
    IGMS F 0.00 1.03
    PCVX D 0.17 1.02
    QURE D -1.11 1.02
    CRNX C -1.70 1.01
    ABUS D 1.45 1.00
    JANX C 8.19 1.00
    AKRO B 4.90 0.99
    REPL B 35.11 0.99
    KROS D 3.86 0.99
    DNLI D 1.94 0.98
    PHVS C 5.94 0.97
    ORIC F 5.15 0.96
    ELVN D -3.42 0.96
    NUVL D 2.37 0.95
    XNCR B 3.78 0.94
    XENE D 3.39 0.91
    RNA D 1.62 0.91
    PLRX F 1.01 0.90
    ANNX F -0.58 0.88
    IMVT F 1.24 0.87
    COGT D 1.67 0.86
    ARQT C -0.98 0.86
    VKTX F 1.86 0.83
    BEAM D 6.23 0.83
    CGON F 3.49 0.82
    CYTK F 3.00 0.82
    RCUS F 2.94 0.80
    BCYC F 1.38 0.78
    MLYS F 5.22 0.78
    ALLO F 4.74 0.77
    NUVB C 3.70 0.76
    ARVN D 2.99 0.74
    ETNB C 4.53 0.74
    VERV F 5.43 0.74
    DYN F -0.13 0.73
    ALEC F 4.79 0.71
    CELC F 3.61 0.71
    MRUS F 2.56 0.70
    ABCL D 1.47 0.69
    ANAB F 5.20 0.68
    VIR D 2.45 0.67
    TERN F 1.40 0.67
    TYRA F 3.06 0.67
    MGNX F 0.93 0.66
    SNDX F 3.14 0.66
    SVRA D 3.70 0.64
    OLMA F 11.56 0.64
    RGNX F 4.47 0.64
    KURA F 7.36 0.64
    CMPS F -0.90 0.63
    LQDA D 4.93 0.63
    ARWR F 1.42 0.61
    LRMR F 0.49 0.60
    AUTL F 3.52 0.59
    IDYA F 0.71 0.59
    STOK F 1.42 0.59
    RLAY F 2.37 0.57
    RXRX F -0.87 0.57
    PRTA F 1.11 0.57
    SLN F -8.72 0.56
    CLDX F 3.05 0.56
    IMTX F 0.13 0.55
    CVAC F 3.91 0.55
    CGEM F 2.62 0.55
    RCKT F 10.32 0.53
    IMNM F 4.25 0.53
    NTLA F 3.62 0.47
    ITOS F 2.34 0.44
    ARCT F -0.94 0.44
    TSHA C 13.30 0.43
    PGEN F -0.03 0.42
    EDIT F 2.95 0.42
    PRME F 7.74 0.37
    LYEL F 3.64 0.37
    FULC F 9.43 0.33
    ZNTL F 1.57 0.32
    FDMT F -2.50 0.31
    SANA F 11.06 0.29
    CABA F 0.00 0.21
    ALXO F 9.30 0.13
    HLVX D 2.20 0.11
    AVTE D 1.92 0.09
    SCLX F -5.57 0.09

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Biotechnology Medicine Cancer Clinical Medicine Life Sciences Biology Immunology Disease Immune System Solid Tumors Antibodies Organ Systems Treatment Of Cancer Autoimmune Disease Genetics Molecular Biology Monoclonal Antibodies Monoclonal Antibody Acute Myeloid Leukemia
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - General Drug Manufacturers - Specialty & Generic Medical Care Facilities

    Recent News for Virtus LifeSci Biotech Clinical Trials ETF & its Holdings

    Date Stock Title
    Nov 23 JANX Janux Therapeutics initiated with an Outperform at Leerink
    Nov 22 IMNM Immunome files to sell 1.80M shares of common stocks by selling shareholders
    Nov 22 REPL S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
    Nov 22 XNCR Xencor: Plamotamab NHL Data Leads To RA Program Advancement
    Nov 22 VKTX Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
    Nov 22 REPL Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
    Nov 22 VKTX Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735
    Nov 22 RXRX 2 Innovative Stocks That Could Deliver Outsize Returns
    Nov 22 XENE JPMorgan Selects These 2 Stocks as Must-Haves for 2025
    Nov 22 VKTX VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
    Nov 22 REPL Replimune climbs after updates on lead drug
    Nov 22 NTLA Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
    Nov 22 SVRA Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
    Nov 22 VKTX RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?
    Nov 22 ARWR Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
    Nov 22 IDYA Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
    Nov 22 CYTK Cytokinetics price target raised to $103 from $99 at Mizuho
    Nov 22 DYN Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
    Nov 22 REPL Replimune's stock surges 19% after-hours on FDA BLA submission
    Nov 22 KURA Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
    The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.
    Biotechnology Health Sciences Drug Discovery Pharmacology Clinical Research Clinical Trial
    Back to the Main BBC Page...